ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
  • ַƸΰЧãϼַҩ۸Ƕ٣

    FDA׼LenvatinibάĪ˾ڿѪƺߡʵоʾоʾȵҩƣLenvatinib+άĪ˾(n = 51)иλPFS14.6 vs 5.5£˽3λOS25.5 vs 15.4£͸ߵĿ͹۷Ӧʣ37% vs 6%ãIJӦкƣ͡ؽʹʹʳ½Ż¡ġǻסǻ֢ѪѹˮסԡʹѡƤ½Ѫ͵򡣡ôƸΰЧΣձѧ߷

  • ͸ΰηַ᣿ϼַЧΣ

    E7080һҰἤøƼӱĽģʽǸеҩҪеVEGFR-1VEGFR-2VEGFR-3FGFR1PDGFRcKitRetַü״ٰ 24mg2Ƭ10mg+1Ƭ4mgÿһΣ18mg1Ƭ10mg+2Ƭ4mgάĪ˾5mgͬÿ1Σΰ12mg/졣ʳͬҪѹܽ򿪽.ڷҩҽἰɲijЩҩͪ³򰷣ᶡҽҪıҩļϸĸáַ

  • E7080᳣ַüʽ_ÿҽ

    Ѫѹ԰ҩܻѪѹѹ100Ѫ˽ϴ;120140 8090 ʳΣѹ140ϵѹ100ҩźۺϱݷѸࣻˮࣻأس㽶ƻؿۼ嵼ҩͬõ(ܿ)ӢSENOKOTݱͨ裻ϷЧͨ೦ȥҽԺӣкήҩЧҪƣƻԣɽҩɽҩƬϸ˿ɺ࣬Լȥ˵ĺ

  • ַٴЧòãЩ÷

    FDA ׼ַlenvatinibάĪ˾EverolimusϲƣʹڼܹѪ֮Ƶϸַ׼ʹϸҪǸһ2ٴооʾַάĪ˾ϲƺάĪ˾һҩȣܸƲļʱ䡢͹۷Ӧʱ䡣 ַάĪ˾ϲǹȥ10һҰἤøƼmTORƼϲƷϸ֤ʵЧķ2ٴ205оһʽĵٴ

  • ַ/طƼ״ٰʱѪѹЩã

    ٴѧ(ASCO)2014ָ±ҩַԷƷӦڷֻļ״ַٰƷӦܣԵ65%߶ȷӦ18.3µļʱ䡣ͿڷҩlenvatinibһֶӰеҰἤøƼԼ VEGF FGFãЩڼ״ٰв방ϸֳĻԡ״ٰзֻͣǼ״ٰ֢ͣԼռ״ٰ85%9ɵIJЧãȴ10%ε״͵ķֻͼ״ٰĿǰѡƷdzޣ

  • תЧ𣿲ע˵

    20149¿ὺҼùʳƷҩƷලܾ(CFDA)Ľע֤ڻתALK+NSCLCȻܿALK+߻λ޽չ(PFS)Ϳ͹ۻ(Oң)᲻ԽѪ-ϣ޷ϵͳALK+ΰ;ңNSCLCϲµĻͣҩʧܡBrigatinibΪᣬΪᡢᡢȡΪcrizotinibпҩԵƷʹòBrigatinibӦתƵĿƺƣԵЧBrigati

  • ַƸΰЧƣһַǶ٣ܳԶã

    طIIIREFLECTо288ߡ2017CSCOϹйʾطλڣmOs顣ֵرעǣйҸԸΰmOsط5£14.9vs.9.9£14.9µmOsйΰ߿ϣ⣬طλ޽չڣ9.2 vs. 3.6£λչʱ䣨11.0 vs. 3.7£Ϳ͹ۻʣ21.5% vs.8.3%Ҫоյ㷽ᣬ2ϡȫȺ

  • ַӹĤЧ

    ַһֶؼøƼıҩ (VEGFR1-3, FGFR1-4, RET, KIT, and PDGFR)Ѫܵ20152016ֱʳƷҩֺ׼ʹڣ(1)ԵЧ֮ԣΪֲڻתֻ֮ͼ״ٰߡ(2) everolimus ܹһֿѪƷϸߡַӹĤٴҲвijɹ˽һ£ַLenvatinibߵڵЧӹĤһҩϲƵٴ顣˵

  • ϸE7080طЧطüЩ

    һġ֮ڶٴ(Study 205)ַlenvatinibǰܹѪƵڻתϸߣ153λ߲飬1:1:1 飬һַ18mgάĪ˾5mgڶַ24mgһ飬άĪ˾10mgһơʾάĪ˾һƵϸߣԼ5.5񻯣ַᵥһ飬Լ7.4²Ŷ񻯣ַϲάĪ˾飬Լ14.6²Ŷ񻯡Ǻϲƣʹַᵥһƣ

  • ֢ͬ״òļͬעЩ?

    ״ٰÿһοڷ24mgϸÿһοڷ18mg Lenvatinib+5mg everolimusάĪ˾ϸÿһοڷ12mgߣƼ״ٰļ14 mgÿһΣϸļ10mgÿһΡַþע1ѪѹLENVIMA֮ǰƸѪѹ֢״3ѪѹӦͣLENVIMAƣвĸѪѹֹơ2˥м˥֢״3˥Ӧжƣ4˥ֹơ3Ѫ˨˨ֶ

  • ϼ̿Ӧ֢ӦЧ÷

    СϸΰĻУԼ5%ALK (anaplastic lymphoma kinase)ںϱ죬ƳʹALKƼЧܺã󲿷ֲںڳALK죬ɿҩԣԲ͸ȲҲٴѡоԱļ137Сϸΰеһڶٴо (NCT01449461)һALKƼо䰲ȫԼЧ71λ֮ǰʹùƵALK-positiveСϸΰУ4λȫӦ40λݷӦӦΪ62%޶񻯴ڿɳ13.2£

  • ҩĻ߻ò_ÿ

    һDZȽԣ˫ۣűǩٴ飨ALTAţNCT02094573222ΪƺչALKԷСϸΰߡ 22290mgIJ飨90mgqd180mgIJ飨ʼ7Ϊ90mgqd180mgqdʵӦ׼RECIST1.1ɶίԱORR90mgORRΪ4895CI3958180mgΪ5395CI43 62λ8º˫λӦʱ䣨DORΪ13.8¡90mg飬4ȫ⣬50ֻ߲

  • 90˼180˼Чһ𣿸Щÿҽ

    ALTA-1Lȫġš飬275δùALKƼڶùһֻƷľֲڻתALK+ NSCLCߡջڵؽеALKȷǷоʸ񡣻߽ALUNBRIG 180ÿһΣ7쵼90ÿһΣcrizotinib 250ÿ2Ρ ALUNBRIGäĶίԱPFScrizotinibձ= 0.49 [95%(CI)0.330.74]log-rank p=0.0007൱ڼչյ51%ALTA-1LʾALUNBRIGһ

  • ò/ЧͼйηñȽϺã

    BrigatinibڵڶALKҩĿǰһڿcrizotinibпҩԻߣƺ޼ʱ(PFS)ԳһҩڰнܹcrizotinibԼδALKƼƵĻߣBrigatinibЧҲߴ73%ALTAожڽܹcrizotinibƣ񻯵ķСϸΰALLͻߣֲͬƣÿ첼Brigatinib 90mg飺112ˣתƻ81ˣÿ첼Brigatinib 180mg飨ÿ90mgһܺټ180mgÿ죩

  • /кЧΣϼ۸Ƕ٣

    ΰǷʺ죬ȺвĶ֮һΰڷٰСϸΰٰռٰԱƤӣEGFR컼ռԼռһ룬EGFR ֮ҩƣԼ5% ڼܰøALK죨ALK ԣALK ҩơ2013 ALK ֮ΰıҩ׶ıҩCrizotinibڴͳҩӻ֮ҸýСʹôҩ߲ƷʡȻCrizotinibԼͨҩԿʼ񻯡

  • ʹòǰ˽⣬зҩ

    BrigatinibһСӿܰøALKƼARIAD Pharmaceuticalsҩ˾ȫӹ˾ 20174£ü׼ALKתԷСϸΰNSCLCߣЩѾչԿ᲻ܡǰ790mgƬODļڷҩܣӵ180mgODbrigatinibηõģͨALKữALK鵼źŵSTAT3AKTERK1 / 2S6ữáԱEML4-ALKϸ17

  • òѪ֢δԤ

    ARIAD ˾һµĵڶALKƼAlunbrigbrigatinibƷΰ2016걻FDA϶ΪNSCLCŶҩ뿹EGFR¡ᵥʹãڿ˷԰ϣҩԡ2017428գFDA׼ᣬƶԿֿܵALKԷСϸΰڵһ90mgƬODļڷҩܣӵ180mgODڷҩڼһЩصĸãиѪǾһALTAУ43A

  • ԭҩAP26113ԳЧ

    ձҩ˾зİҩᡢ򲼸ᡣͿһALK,ROS1,MetALKͻСϸΰߣڰϣͿҩѡĿǰΨһһEGFRALKеİҩDzƷòͣл߻ʳԲԭҩap26113?DzҲЧ˽һ²ԭҩap26113AP26113ԭҩҩԭϣΪûоڵļӹ׳ܽٶ̫׳ûз

  • ἤøCPKҲǷòḱ֮һ𣿵Ը

    ᡢ򲼸ᡣӢΪbrigatinibҩƷAlunbrig ĿǰALKڷСϸΰڰϣͿҩѡĿǰΨһһEGFRALKеİҩձҩ˾зİҩͿһALK,ROS1,MetALKͻСϸΰߣڿҩѡ񲼼ᡣἤøCPKߣALTAУ90mgнALUNBRIGĻ27ἤøCPKߣ90mg180mgн48Ļߡ90mg

  • òʱĶøεҩ

    ᡢ򲼸ᡣӢΪbrigatinibҩƷAlunbrig ĿǰALKڷСϸΰڰϣͿҩѡĿǰΨһһEGFRALKеİҩձҩ˾зİҩͿһALK,ROS1,MetALKͻСϸΰߣڿҩѡ񲼼ᡣôڷòʱᷢһЩصĸҪرעģʹڼ䷢ĶεʹüʽALUN

共有95页首页上一页123456789下一页尾页
客服中心
联系方式
400-001-9763
- ѯ
ɨάѯ